1. Patient-directed Volume Reduction for Emphysema: Sequential Surgical and Endobronchial Techniques
- Author
-
David A. Waller, Inger Oey, Mike Morgan, and Michael C Steiner
- Subjects
Adult ,Male ,Pulmonary and Respiratory Medicine ,Lung volume reduction ,medicine.medical_specialty ,030204 cardiovascular system & hematology ,Lung volume reduction surgery ,03 medical and health sciences ,0302 clinical medicine ,Forced Expiratory Volume ,medicine ,Humans ,Volume reduction ,Lung volumes ,Longitudinal Studies ,Pneumonectomy ,Residual volume ,Lung ,Lung function ,Aged ,Thoracic Surgery, Video-Assisted ,business.industry ,Open surgery ,Total Lung Capacity ,Endobronchial valve ,Middle Aged ,Surgery ,Treatment Outcome ,Pulmonary Emphysema ,030228 respiratory system ,Female ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Lung volume reduction (LVR) surgery has traditionally been performed as a 1-stage bilateral procedure or staged at a predetermined interval. However to maximize the overall benefit we have allowed the patient to determine the timing of further interventions and have added endobronchial LVR into the protocol. We have reviewed the long-term outcome.Three hundred thirty-one LVR procedures were performed on 254 patients (median age, 61 years [range, 23-79]) with baseline predicted lung function of (mean ± SD) forced expiratory volume in 1 second 28% ± 11% and residual volume 253% ± 53%. The initial procedure was by video-assisted thoracoscopic surgery in 236 patients (unilateral, 227; bilateral, 9), by open surgery in 5, and by endobronchial valve insertion in 13. Sixty-four patients received a second and 13 a third LVR procedure. The median time interval between first and third stage was 5.8 years (range, 1.9-10) RESULTS: In the subgroup of patients who underwent staged procedures there was a significant improvement in predicted forced expiratory volume in 1 second from 28% at baseline to 34% up to 6 years. There was sustained reduction in static lung volumes up to 8 years: Predicted residual volume remained reduced from 259% to 189%. There were sustained improvements over baseline in health status: EuroQol-5D improved from 50 ± 26 to 62 ± 23 (P.01) for up to 5 years and the Short Form 36-item questionnaire for up to 9 years. Overall 30-day mortality was 3%. Median survival was 5.6 years (95% confidence interval, 4.7-6.9).A program of staged unilateral procedures of LVR has resulted in sustained benefits for up to 9 years in physiology and health status.
- Published
- 2021